Lipid metabolism genes in contralateral unaffected breast and estrogen receptor status of breast cancer

Cancer Prevention Research

Volumn 6, Issue 4, 2013, Pages 321-330

  Wang, Jun ^a   Scholtens, Denise ^a   Holko, Michelle ^a   Ivancic, David ^a   Lee, Oukseub ^a   Hu, Hong ^a   Chatterton, Robert T ^a   Sullivan, Megan E ^a   Hansen, Nora ^a   Bethke, Kevin ^a   Zalles, Carola M ^b   Khan, Seema A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Mercy Hospital Miami   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; LIPID;

AGE; ARTICLE; BREAST CANCER; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENE EXPRESSION; HUMAN; LIPID METABOLISM; MALE; MENOPAUSE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RACE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84877292290     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0304     Document Type: Article

References (49)

1. Hankinson SE, Colditz GA, Willett WC. Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res 2004;6:213-8.
2. Vona-Davis L, Howard-McNatt M, Rose DP. Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev 2007;8: 395-408. (Pubitemid 47283945)
3. Friedenreich CM, Orenstein MR. Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr 2002;132: 3456S-64S. (Pubitemid 35315820)
4. Kendall A, Folkerd EJ, Dowsett M. Influences on circulating oestrogens in postmenopausal women: relationship with breast cancer. J Steroid Biochem Mol Biol 2007;103:99-109. (Pubitemid 46149297)
5. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 2011;103:250-63.
6. Chlebowski RT, Anderson GL, Lane DS, Aragaki AK, Rohan T, Yasmeen S, et al. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst 2007;99:1695-705. (Pubitemid 351767220)
7. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86. (Pubitemid 20026073)
8. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146-51. (Pubitemid 15192861)
9. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, et al. Benign breast disease and the risk of breast cancer. N Engl J Med 2005;353:229-37. (Pubitemid 41058322)
10. McCormack VA, dos SS I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006;15:1159-69.
11. Kerlikowske K, Ichikawa L, Miglioretti DL, Buist DS, Vacek PM, Smith-Bindman R, et al. Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk. J Natl Cancer Inst 2007;99:386-95. (Pubitemid 47073482)
12. Becker S, Kaaks R. Exogenous and endogenous hormones, mammographic density and breast cancer risk: can mammographic density be considered an intermediate marker of risk? Recent Results Cancer Res 2009;181:135-57.
13. Stark A, Hulka BS, Joens S, Novotny D, Thor AD, Wold LE, et al. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J Clin Oncol 2000;18:267-74. (Pubitemid 30056414)
14. Gobbi H, Dupont WD, Simpson JF, Plummer WD Jr, Schuyler PA, Olson SJ, et al. Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. J Natl Cancer Inst 1999;91:2096-101. (Pubitemid 30019570)
15. Visscher DW, Pankratz VS, Santisteban M, Reynolds C, Ristimaki A, Vierkant RA, et al. Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. J Natl Cancer Inst 2008;100:421-7. (Pubitemid 351480513)
16. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88. (Pubitemid 28439961)
17. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41.
18. Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364:2381-91.
19. Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 2003;95:526-32. (Pubitemid 36511623)
20. Swain SM, Wilson JW, Mamounas EP, Bryant J, Wickerham DL, Fisher B, et al. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst 2004;96:516-23. (Pubitemid 38559575)
21. Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA. Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst 2009;101:1058-65.
22. Bouchardy C, Benhamou S, Fioretta G, Verkooijen HM, Chappuis PO, Neyroud-Caspar I, et al. Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Res Treat 2011;127:233-41.
23. Euhus DM, Cler L, Shivapurkar N, Milchgrub S, Peters GN, Leitch AM, et al. Loss of heterozygosity in benign breast epithelium in relation to breast cancer risk. J Natl Cancer Inst 2002;94:858-60. (Pubitemid 34705059)
24. Fabian CJ, Kimler BF, Zalles CM, Klemp JR, Kamel S, Zeiger S, et al. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst 2000;92: 1217-27. (Pubitemid 30627730)
25. Masood S, Frykberg ER, McLellan GL, Scalapino MC, Mitchum DG, Bullard JB. Prospective evaluation of radiologically directed fine-needle aspiration biopsy of nonpalpable breast lesions. Cancer 1990;66: 1480-7. (Pubitemid 20355413)
26. The uniform approach to breast fine-needle aspiration biopsy. National Cancer Institute fine-needle aspiration of breast workshop subcommittees. Diagn Cytopathol 1997;16:295-311.
27. Khan QJ, Kimler BF, Clark J, Metheny T, Zalles CM, Fabian CJ. Ki-67 expression in benign breast ductal cells obtained by random periareolar fine needle aspiration. Cancer Epidemiol Biomarkers Prev 2005;14:786-9. (Pubitemid 40478536)
28. Sharma P, Kimler BF, Warner C, Metheny T, Xue Q, Zalles CM, et al. Estrogen receptor expression in benign breast ductal cells obtained from random periareolar fine needle aspiration correlates with menopausal status and cytomorphology index score. Breast Cancer Res Treat 2006;100:71-6.
29. Bean GR, Bryson AD, Pilie PG, Goldenberg V, Baker JC Jr, Ibarra C, et al. Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF. Clin Cancer Res 2007;13:6834-41. (Pubitemid 350206822)
30. Bean GR, Ibarra DC, Goldenberg VK, Baker JC Jr, Troch MM, Paisie C, et al. Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk. Cancer Epidemiol Biomarkers Prev 2007;16:50-6. (Pubitemid 46174263)
31. Baker JC Jr, Ostrander JH, Lem S, Broadwater G, Bean GR, D'Amato NC, et al. ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention. Cancer Epidemiol Biomarkers Prev 2008;17:1884-90.
32. Vasilatos SN, Broadwater G, Barry WT, Baker JC Jr, Lem S, Dietze EC, et al. CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis. Cancer Epidemiol Biomarkers Prev 2009;18:901-14.
33. Euhus DM, Bu D, Milchgrub S, Xie XJ, Bian A, Leitch AM, et al. DNA methylation in benign breast epithelium in relation to age and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2008;17:1051-9.
34. Lewis CM, Cler LR, Bu DW, Zochbauer-Muller S, Milchgrub S, Naftalis EZ, et al. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res 2005;11: 166-72. (Pubitemid 40081117)
35. Petroff BK, Phillips TA, Kimler BF, Fabian CJ. Detection of biomarker gene expression by real-time polymerase chain reaction using amplified ribonucleic acids from formalin-fixed random periareolar fine needle aspirates of human breast tissue. Anal Quant Cytol Histol 2006;28:297-302. (Pubitemid 44622506)
36. Finak G, Sadekova S, Pepin F, Hallett M, Meterissian S, Halwani F, et al. Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. Breast Cancer Res 2006;8:R58.
37. Graham K, de Las MA, Tripathi A, King C, Kavanah M, Mendez J, et al. Gene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile. Br J Cancer 2010;102:1284-93.
38. Graham K, Ge X, de Las MA, Tripathi A, Rosenberg CL. Gene expression profiles of estrogen receptor-positive and estrogen receptor-negative breast cancers are detectable in histologically normal breast epithelium. Clin Cancer Res 2011;17:236-46.
39. Tripathi A, King C, de la Morenas A, Perry VK, Burke B, Antoine GA, et al. Gene expression abnormalities in histologically normal breast epithelium of breast cancer patients. Int J Cancer 2008;122:1557-66. (Pubitemid 351294964)
40. Fagherazzi G, Chabbert-Buffet N, Fabre A, Guillas G, Boutron-Ruault MC, Mesrine S, et al. Hip circumference is associated with the risk of premenopausal ER-/PR-breast cancer. Int J Obes (Lond) 2012;36: 431-9.
41. Eliassen AH, Missmer SA, TworogerSS, Hankinson SE. Circulating 2-hydroxy- and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008;17:2029-35.
42. Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst 2006;98:1767-76. (Pubitemid 46017928)
43. Blevins-Primeau AS, Sun D, Chen G, Sharma AK, Gallagher CJ, Amin S, et al. Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res 2009;69:1892-900.
44. Mitra PS, Basu NK, Owens IS. Src supports UDP-glucuronosyltransferase-2B7 detoxification of catechol estrogens associated with breast cancer. Biochem Biophys Res Commun 2009;382:651-6.
45. Haakensen VD, Biong M, Lingjaerde OC, Holmen MM, Frantzen JO, Chen Y, et al. Expression levels of uridine 5'-diphospho-glucuronosyl-transferase genes in breast tissue from healthy women are associated with mammographic density. Breast Cancer Res 2010;12:R65.
46. Deisenroth C, Thorner AR, Enomoto T, Perou CM, Zhang Y. Mitochondrial Hep27 is a c-Myb target gene that inhibits Mdm2 and stabilizes p53. Mol Cell Biol 2010;30:3981-93.
47. Greenland KJ, Jantke I, Jenatschke S, Bracken KE, Vinson C, Gellersen B. The human NAD+-dependent 15-hydroxyprostaglandin dehydro-genase gene promoter is controlled by Ets and activating protein-1 transcription factors and progesterone. Endocrinology 2000;141: 581-97. (Pubitemid 32250482)
48. Lehtinen L, Vainio P, Wikman H, Reemts J, Hilvo M, Issa R, et al. 15-hydroxyprostaglandin dehydrogenase associates with poor prognosis in breast cancer, induces epithelial-mesenchymal transition and promotes cell migration in cultured breast cancer cells. J Pathol 2012; 226:674-86.
49. Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 1996;274: 2057-9. (Pubitemid 27020695)